Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Definition||A kidney cancer that derives_from the lining of the proximal convoluted tubule (the very small tubes in the kidney that filter the blood and remove waste products).|
|Path||disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma|
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Unknown unknown||Cabozantinib||renal carcinoma||not applicable||detail...|
|Unknown unknown||MG 98||renal carcinoma||no benefit||detail...|
|Unknown unknown||Hydroxyurea + MU380||renal carcinoma||not applicable||detail...|
|Unknown unknown||R916562||renal carcinoma||not applicable||detail...|
|Unknown unknown||MRx0518||renal carcinoma||not applicable||detail...|
|Unknown unknown||PF-06840003||renal carcinoma||not applicable||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03050060||Phase II||Nelfinavir + Nivolumab||Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer||Suspended|
|NCT04095273||Phase I||BAY1895344 + Pembrolizumab||Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug||Recruiting|